Eshoo Introduces Bill to Improve Foreign Drug Manufacturing Reporting

Statement

Today Rep. Anna G. Eshoo (D-CA) introduced H.R. 6483, the Improved Transparency of Foreign Drug Manufacturing Act, legislation that directs the Food and Drug Administration (FDA) to collect additional information on drugs and the active pharmaceutical ingredients (APIs) that are manufactured overseas every 3 months instead of annually. This will help to better identify the drugs that are most dependent on foreign supply chains.

"Our nation's dependence on foreign countries to manufacture critical drugs is unacceptable and poses a serious national security threat to America. Today, the FDA lacks timely information to assess exactly what drugs and APIs are manufactured by foreign countries. The bill directs quarterly reports from foreign drug manufactures, rather than annual reporting," said Rep. Eshoo.

Source